Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13560502 | 0.81 | DGAT1 (0.35) | MAPTNPSR1DGAT1 | |
| SCHEMBL3635281 | 0.80 | DGAT1 (0.35) | MAPTNPSR1DGAT1BRD4CREBBP | |
| SCHEMBL3028008 | 0.79 | DGAT1 (0.38) | MAPTDGAT1POLBPKM | |
| SCHEMBL28841318 | 0.78 | DGAT1 (0.37) | MAPTNPSR1DGAT1BRD4CREBBP | |
| SCHEMBL31340868 | 0.76 | FDPS (0.45) | — | |
| SCHEMBL357273 | 0.76 | FDPS (0.45) | — | |
| SCHEMBL31138390 | 0.76 | DGAT1 (0.36) | MAPTDGAT1 | |
| SCHEMBL9928488 | 0.76 | DGAT1 (0.36) | MAPTDGAT1 | |
| SCHEMBL3267555 | 0.76 | P2RX7 (0.43) | MAPTDGAT1 | |
| SCHEMBL12620882 | 0.76 | ADORA2A (0.37) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739393-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | Merck Sharp & Dohme LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-4642782-A2 | ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF | Pliant Therapeutics, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-4554933-A1 | HERBICIDAL IMIDAZOLE COMPOUNDS | Syngenta Crop Protection AG (CH) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-119451949-A | Herbicidal imidazole compounds | 先正达农作物保护股份公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20250026759-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | MERCK SHARP & DOHME LLC (US) | 2025-01-23 | — | — | US | disclosed |
| WO-2025014788-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | MERCK SHARP & DOHME LLC (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2024013018-A1 | HERBICIDAL IMIDAZOLE COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2024-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026759-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | ACIN1, REV1, NFATC1 | MAPT 2556/4885NPSR1 4707/4885DGAT1 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.